October, 2016
First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002
NanoMedSyn
September, 2016
Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe’s disease. EMA (EU/3/16/1726)
September, 2016
Lire l’article complet
June, 2016
Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours Tremplin Entreprises.
November, 2015
November, 2015
Information reliée par l’Académie des sciences
September, 2015
Published by ECOMNEWS on September 1st, 2015 Publihed by BIOTECHFINANCES on September 4th, 2015 Published by Heraultjuridique.com on September 7th, 2015
April, 2015
Review in Languedoc-Roussillon Magazine, L’accent du Sud, N°38, p9” on Medical Research: “Nanoparticles to fight cancer”.
December, 2014
Increase of capital funding of NanoMedSyn for internal R &D in lysosomal diseases and cancer.
April, 2014
NanoMedSyn signs a 3-year cooperative grant in the program «Program Nanotechnologies and Nanosystems (P2N)”, with Agence Nationale de la Recherche: “BIOSIPHARM: Biosafety of mesoporous silica nanoparticles according to their surface coverage and establishing standards for evaluation”. Partners: Institute Charles Gerhardt,…